Phase IV, randomized, open-label, open-label, controlled, parallel, multicenter clinical trial in patients who are candidates for smoking cessation to evaluate the safety and efficacy of citisinicline maintenance therapy.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518936-36-00

Acronym

CITISILONG

Enrollment

400

Registered

2025-05-05

Start date

2026-01-23

Completion date

Unknown

Last updated

2025-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Active smokers

Brief summary

It will be carried out by evaluating punctual and continuous abstinence at 3, 6 and 12 months., The safety results will be carried out by evaluating the incidence of the side effects foreseen in the technical data sheet.

Interventions

DRUGRecigarum 1

DRUG5 mg comprimidos recubiertos con película EFG

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
It will be carried out by evaluating punctual and continuous abstinence at 3, 6 and 12 months., The safety results will be carried out by evaluating the incidence of the side effects foreseen in the technical data sheet.	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026